Antioxidants inhibit neuronal toxicity in Parkinson's disease‐linked LRRK2. Issue 4 (2nd March 2016)

• Record Type: Journal Article
• Authors: Angeles, Dario C.; Ho, Patrick; Dymock, Brian W.; Lim, Kah‐Leong; Zhou, Zhi‐Dong; Tan, Eng‐King
• Is Part Of: Annals of clinical and translational neurology. Volume 3:Issue 4(2016)
• Page Start: 288
• Page End: 294
• Publication Date: 2016-03-02
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.282
• Languages: English
• ISSNs: 2328-9503

Abstract

Abstract: Mutations in leucine‐rich repeat kinase‐2 are the most common cause of familial Parkinson's disease. The prevalent G2019S mutation increase oxidative, kinase and toxic activity and inhibit endogenous peroxidases. We initially screened a library of 84 antioxidants and identified seven phenolic compounds that inhibited kinase activity on leucine‐rich repeat kinase‐2 substrates. The representative antioxidants (piceatannol, thymoquinone, and esculetin) with strong kinase inhibitor activity, reduced loss in dopaminergic neurons, oxidative dysfunction, and locomotor defects in G2019S‐expressing neuronal and Drosophila models compared to weak inhibitors. We provide proof of principle that natural antioxidants with dual antioxidant and kinase inhibitor properties could be useful for leucine‐rich repeat kinase‐2‐linked Parkinson's disease.